Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms
    Journal Article

    Stivala, S.; Codilupi, T.; Brkic, S.; Baerenwaldt, A.; Ghosh, N.; Hao-Shen, H.; Dirnhofer, S.; Dettmer, M. S.; Simillion, C.; Kaufmann, B. A.; more...
    Journal of Clinical Investigation (2019)

    Fulltext@MSK | Save
  • BRAF in the cross-hairs
    Review

    Geyer, M. B.; Abdel-Wahab, O.; Tallman, M. S.
    Expert Review of Hematology (2019)

    Fulltext@MSK | Save
  • CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response
    Journal Article

    Kuhn, N. F.; Purdon, T. J.; van Leeuwen, D. G.; Lopez, A. V.; Curran, K. J.; Daniyan, A. F.; Brentjens, R. J.
    Cancer Cell (2019)

    Fulltext@MSK | Save
  • The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia
    Journal Article

    Yeshurun, M.; Weisdorf, D.; Rowe, J. M.; Tallman, M. S.; Zhang, M. J.; Wang, H. L.; Saber, W.; de Lima, M.; Sandmaier, B. M.; Uy, G.; more...
    Blood Advances (2019)

    Fulltext@MSK | Save
  • PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
    Journal Article

    Gu, Z.; Churchman, M. L.; Roberts, K. G.; Moore, I.; Zhou, X.; Nakitandwe, J.; Hagiwara, K.; Pelletier, S.; Gingras, S.; Berns, H.; more...
    Nature Genetics (2019)

    Fulltext@MSK | Save
  • LeukeMYC prognostication
    Editorial

    Knorr, K. L. B.; Tallman, M. S.
    Leukemia and Lymphoma (2019)

    Fulltext@MSK | Save
  • Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia
    Journal Article

    Leeksma, A. C.; Taylor, J.; Wu, B.; Gardner, J. R.; He, J.; Nahas, M.; Gonen, M.; Alemayehu, W. G.; te Raa, D.; Walther, T.; more...
    Leukemia (2019)

    Fulltext@MSK | Save
  • Novel tyrosine kinase inhibitors for patients with inadequate response in chronic myeloid leukemia
    Review

    Mauro, M. J.
    Current Opinion in Hematology (2019)

    Fulltext@MSK | Save
  • First CAR to pass the road test: Tisagenlecleucel's drive to FDA approval
    Journal Article

    Geyer, M. B.
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib
    Journal Article

    Stein, E. M.; DiNardo, C. D.; Fathi, A. T.; Pollyea, D. A.; Stone, R. M.; Altman, J. K.; Roboz, G. J.; Patel, M. R.; Collins, R.; Flinn, I. W.; more...
    Blood (2019)

    Fulltext@MSK | Save